Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $66.84 -0.39%
EPS Growth %: -215.1%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: -215.1%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
